CBD Eye Drops Cut Intraocular Pressure in Glaucoma Mice, Study Finds

Twice-daily dosing of a water-soluble CBD eye formulation produced significant, sustained reductions in intraocular pressure in mice genetically predisposed to glaucoma, according to a study published November 10 in the European Journal of Pharmacology. Researchers at Rey Juan Carlos University in Spain also recorded a persistent drop in corneal sensitivity — an effect that outlasted the treatment itself.

The finding matters because intraocular pressure is the primary modifiable risk factor in glaucoma, a leading cause of irreversible blindness worldwide. Existing pressure-lowering medications do not always halt disease progression and frequently cause ocular discomfort, leaving room for adjunct therapies. Whether CBD can fill that gap is a question this mouse study begins, but does not settle.

What did the researchers actually test?

The team evaluated a newly developed water-soluble CBD formulation administered directly to the eye, in both short-term and repeated dosing regimens, including once-daily and twice-daily schedules. They used glaucoma-predisposed mice alongside a non-glaucoma strain as a comparison group. Throughout the study, they tracked four measurable endpoints: intraocular pressure, tear production, corneal sensitivity and body weight.

The results separate cleanly into measured findings and open questions. CBD initially produced a temporary increase in eye pressure before continued treatment reversed the effect. Repeated administration then led to significant, sustained pressure reductions, strongest with twice-daily dosing. The study text does not report the magnitude of those reductions in numerical terms, which limits how far the findings can be compared against existing pressure-lowering agents.

To probe for systemic effects, the researchers measured untreated eyes in the same animals. Pressure changes there were smaller and inconsistent, indicating the therapeutic effect was localized to the treated eye rather than systemic — a relevant property for an ocular drug candidate.

What happened to corneal sensitivity?

CBD significantly raised the threshold at which mice responded to mechanical stimulation of the cornea, meaning the animals perceived touch at higher intensities. That indicates reduced corneal sensitivity, which the authors frame as relevant to the abnormal corneal sensitivity associated with glaucoma.

The durability data diverge in a way portfolio managers should note. Reduced corneal sensitivity persisted even after treatment stopped, while intraocular pressure returned toward baseline following withdrawal. The pressure benefit, in other words, is maintenance-dependent; the sensory effect is not. The mechanism behind that persistence is not addressed in the reported findings.

Tolerability signals were clean within the study's scope: no significant changes in tear production or body weight in either mouse strain, suggesting the formulation was well tolerated under repeated administration.

Who funded the work, and what is not said?

The study was funded by Laboratoire Laredo, a company that holds a European patent covering the water-soluble CBD formulation used in the research. The funder therefore holds a direct commercial interest in a positive result, and the study is preclinical — mice, not humans, with no sample sizes disclosed in the available reporting. Translation to human glaucoma patients remains untested, and the initial pressure spike observed early in treatment would warrant scrutiny in any subsequent work.

Where does this sit in the wider evidence base?

The mouse data arrive amid a cluster of related findings. A separate study published in October found that a CBD eye treatment incorporating nanoparticles and a temperature-sensitive gel significantly reduced intraocular pressure in rabbits. Earlier in November, an observational study of more than 25,000 people — roughly the population of a mid-sized university town — reported that daily marijuana use was associated with 39% lower odds of primary open-angle glaucoma.

The researchers say their findings support topical CBD as a potential additional therapeutic approach addressing both elevated eye pressure and abnormal corneal sensitivity in glaucoma. That claim currently rests on a patent-holder-funded mouse model; human trials, dosing standards and long-term safety data are the necessary next steps before it can inform clinical decisions.